JazzPharma Announces First Patient Enrolled in IMforte Phase 3 Trial Evaluating Zepzelca® (lurbinectedin) in Combination with a PD-L1 Inhibitor in Small Cell Lung Cancer . Un Ensayo Que está Previsto Que Sea Completado el 1 de Marzo 2025 .